文献速递呼吸道感染呼吸危重症与机械通气

培养阴性医院获得性肺炎中降阶梯停用抗MRSA药物的结局

Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia.
PubMed 文献 · Chest · 2018-10-25

本研究为单中心回顾性队列,纳入2012至2017年培养阴性的医院获得性肺炎成人患者279例,比较4天内停用抗MRSA药物(降阶梯)与未降阶梯者的结局。降阶梯组28天死亡率与未降阶梯组无差异,但住院时间更短、急性肾损伤发生率更低。

要点

  • 培养阴性医院获得性肺炎中,4天内停用抗MRSA药物未增加28天死亡率。
  • 降阶梯与更短住院时间及更低急性肾损伤发生率相关。
  • 未降阶梯者接受抗MRSA覆盖时间比降阶梯者多5天。

核心结论

  • 培养阴性医院获得性肺炎中停用抗MRSA药物不影响28天死亡率,与更短住院时间和更低急性肾损伤发生率相关。

研究设计与样本

  • 单中心回顾性队列研究,纳入2012至2017年培养阴性的医院获得性肺炎成人患者279例,降阶梯组92例、未降阶梯组187例。

主要发现

  • 28天死亡率未降阶梯组28%、降阶梯组23%,差值-5.5%(95%CI -16.1至6.5)。
  • 降阶梯组住院时间15天、未降阶梯组20天,差值3.2天(95%CI 0.1至6.4)。
  • 降阶梯组ICU时间10天、未降阶梯组13天,差值2.2天(95%CI -0.3至4.9)。
  • 急性肾损伤发生率降阶梯组36%、未降阶梯组50%,差值-13.8%(95%CI -26.9至-0.4)。
  • 未降阶梯者接受抗MRSA覆盖时间比降阶梯者多5天。

临床怎么用

  • 对培养阴性的医院获得性肺炎,可考虑在4天内停用经验性抗MRSA药物以缩短住院时间并减少急性肾损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In culture-positive nosocomial pneumonia, de-escalation (DE) from broad-spectrum empirical antimicrobials to narrower-spectrum agents has shown to decrease broad-spectrum antibiotic use without compromising patient outcomes. However, uncertainty exists regarding the safety of anti-methicillin-resistant Staphylococcus aureus (MRSA) agent DE in culture-negative nosocomial pneumonia. This study aimed to determine if anti-MRSA agent DE in culture-negative nosocomial pneumonia affects 28-day and hospital mortality, ICU and hospital length of stay (LOS), treatment failure, and safety. METHODS: This single-center retrospective cohort study included adult patients admitted from 2012 to 2017 with nosocomial pneumonia and a negative respiratory culture. DE was defined as anti-MRSA agent discontinuation within 4 days of initiation. Secondary outcomes included hospital mortality, hospital and ICU LOS, treatment failure, and occurrence of acute kidney injury (AKI). RESULTS: Of 279 patients included, 92 were in the DE group and 187 were in the no DE (NDE) group. Patients who were not de-escalated received 5 more days of MRSA coverage than patients who were de-escalated; however, there was no difference in 28-day mortality (NDE group, 28% vs DE group, 23%; difference, -5.5%; 95% CI, -16.1 to 6.5). Patients who were de-escalated had shorter hospital (DE group, 15 days vs NDE group, 20 days; difference, 3.2 days; 95% CI, 0.1-6.4) and ICU (DE group, 10 days vs NDE group, 13 days; difference, 2.2 days; 95% CI, -0.3 to 4.9) LOSs after the index date. The incidence of AKI was significantly higher in patients who were not de-escalated (DE group, 36% vs NDE group, 50%; difference, -13.8%; 95% CI, -26.9 to -0.4). CONCLUSIONS: Although anti-MRSA agent DE in culture-negative nosocomial pneumonia did not affect 28-day mortality, it was associated with a shorter hospital LOS and lower incidence of AKI.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Cowley MC, Ritchie DJ, Hampton N, et al. Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia. Chest. 2018. PMID: 30621854. doi:10.1016/j.chest.2018.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。